Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.

Handbook of experimental pharmacology - 1 Jan 2000

Sartore-Bianchi Andrea, Siena Salvatore

Abstract excerpt

Colorectal cancer (CRC) is one of the most prevalent cancers and the second leading cause of cancer mortality worldwide. Survival in the metastatic setting has been gradually improved by the addition to cytotoxic chemotherapy of agents targeting the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Considerable heterogeneity exists within CRC due to the varied genetic and...

Topics

Join the communities discussing this publication.

Antibodies, Monoclonal
Antineoplastic Agents
Colorectal Neoplasms
Drug Resistance, Neoplasm
ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Metastasis

Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 28382467
DOI: 10.1007/164_2017_19

Genes

EGFR
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.PMID 28382467Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer PatientsSemantic proximity Read ↗

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.Semantic proximity Read ↗

Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionSemantic proximity Read ↗

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancerSemantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Genetic Alterations of Metastatic Colorectal CancerSemantic proximity Read ↗

The genomic landscape of response to EGFR blockade in colorectal cancer.Semantic proximity Read ↗

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just geneticsSemantic proximity Read ↗

The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?Semantic proximity Read ↗

Molecular features and gene expression signature of metastatic colorectal cancer (Review)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.